Gilead Submits New Drug Application to U.S. FDA for Once-Daily, Single-Tablet "Quad" HIV Regimen
Links shared publicly online about this topic.
- 0total visits
Gilead Submits New Drug Application to U.S. FDA for Once-Daily, Single-Tablet "Quad" HIV Regimen
Quad HIV Regimen (cobicistat, elvitegravir, emtricitabine and tenofovir) is a new drug combinaton in development for the treatment of HIV infection. Quad HIV Regimen information includes news, clinical trial results and side effects.
View full resource at drugs.com
Tags: HIV, HIV Medication, STD, Drug, FDA, Viread, Emtriva
Most Recently Shared on October 31, 2011 at 2:17 am By:
Gilead Submits New Drug Application to U.S. FDA for Once-Daily, Single-Tablet "Quad" HIV Regimen: FOSTER C... http://t.co/zuS71OJg #drug
Gilead Sciences Submits New Drug Application To U.S. FDA For Once-Daily Single-Tablet Regimen Of Truvada(R) And TMC278 For HIV
medicalnewstoday.com — “Gilead Sciences, Inc. (Nasdaq:GILD) announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of the single-tablet regimen” View full resource at medicalnewstoday.com
Most Recently Shared on November 26, 2010 at 2:05 pm By:
Gilead Sciences Submits New Drug Application To U.S. FDA For Once-Daily Single-Tablet Regimen Of Truvada(R) And TMC278... http://mnt.to/3N9K
Advertisement
